Profile of Antibiotic Use and Germ Map in Pneumonia Patients in Pulmonary Space (Case Study at RSUD dr. Iskak. Tulungagung)

Abstract

Pneumonia is an infection of lung tissue caused by bacteria, fungi, viruses or parasites. Antibiotics is a major therapy in pneumonia. The aim of this study was to determine the amount of antibiotic use in DDD / 100 patient-days and to know the profile of germs map in pneumonia patients in Pulmonary Room Dr. Iskak Hospital, Tulungagung during January-June 2017.The design of this research is observational research method with retrospective data retrieval from patient medical record data and antibiotic usage data from Pharmacy Installation and microbiology culture result data of patient, then analyzed descriptively. The results showed the total amount of antibiotic in 130 unspecified pneumonia patients non ICU inpatient in Pulmonary Room Dr. Iskak Hospital, Tulungagung during January-June 2017 was 51.28 DDD/100 patient-days. The most antibiotic types are levofloxacin iv 40, 14 DDD/100 patient-days and ceftriaxone 8.71 DDD/100 patient-days. The profile of the pneumonia-causing germs map cannot be determined because there is no data on microbiological culture test results from the patient.

Assessment of Antibiotic Use in ICU Patients with Pneumonia Using ATC/DDD as a Quantitative Analysis Method

“…Compared to 98 studies conducted in hospitals in Germany that showed total antibiotic use in sepsis and pneumonia patients of 51.0 DDD/100 patient-days (Scholze et al, 2015) Parenteral Levofloxacin is the most widely used antibiotic in RSUA Surabaya. Similarly, it was found in studies conducted at Dr Iskak Tulungagung Hospital and Dr Moewardi Surakarta Hospital, with the number of Levofloxacin used for consecutive indications of pneumonia reaching 40.14 DDD/100 patient-days and 53.88 DDD/100 patient-days (Ilmi et al, 2020;Muhammad & Mutmainah, 2018). Levofloxacin is among the most widely prescribed types of antibiotics for pneumonia therapy because it is a respiratory fluoroquinolone-class antibiotic that is effective overcoming upper and lower airway infections with high activity against gram-positive bacteria and atypical bacteria cause pneumonia (Daniel H & Lisa G, 2015;Izadi et al, 2019).…”

Review: Application of the Atc/DDD Method for Antibiotic Evaluation in Indonesia

“…When evaluating the use of antibiotics before and after intervention, for example, Guidelines for Antibiotic Use (PPAB) (Karuniawati et al, 2021), Antimicrobial Resistance Control Program (PPRA) (Kartika et al, 2019), and Clinical Pathway (Adiwisastra et al, 2019). (Evano Putra et al, 2021) and (Ilmi et al, 2020) selected pneumonia patients in the lung room at the RSUD dr. Iskak Tulungagung for their case studies on the use of antibiotics during the Covid-19 pandemic at the Diponegoro National Hospital. The duration of the investigation period for the selected articles ranged from one month to five years.…”